1 line
3.2 KiB
JSON
1 line
3.2 KiB
JSON
{"actinic keratosis": 119.02, "acute respiratory distress syndrome": 3.73, "agitation": 2.2, "alanine aminotransferase increased": 3.75, "altered state of consciousness": 2.24, "aspartate aminotransferase increased": 2.96, "aspergillus infection": 74.21, "blood alkaline phosphatase increased": 8.2, "blood bilirubin increased": 2.58, "bone disorder": 3.52, "bone pain": 2.23, "brain abscess": 25.45, "bronchopulmonary aspergillosis": 58.11, "candida infection": 7.53, "chloropsia": 206.08, "cholestasis": 11.68, "chromatopsia": 40.28, "condition aggravated": 3.3, "confusional state": 2.09, "delirium": 11.68, "dermatitis bullous": 3.25, "disease progression": 2.63, "disorganised speech": 59.67, "drug ineffective": 5.02, "drug ineffective for unapproved indication": 14.84, "drug interaction": 9.34, "drug intolerance": 3.32, "drug level above therapeutic": 40.17, "drug level below therapeutic": 71.48, "drug level decreased": 27.61, "drug level increased": 21.25, "drug resistance": 23.46, "drug-induced liver injury": 21.86, "dyschromatopsia": 37.0, "dysphoria": 3.15, "electrocardiogram qt prolonged": 7.29, "electrolyte imbalance": 4.38, "encephalopathy": 2.9, "eye disorder": 3.87, "fluoride increased": 1204.52, "fluorosis": 1760.22, "fungal infection": 9.5, "fusarium infection": 121.83, "gamma-glutamyltransferase increased": 5.08, "haemoptysis": 2.59, "hallucination": 24.16, "hallucination, auditory": 15.01, "hallucination, visual": 51.4, "hallucinations, mixed": 14.19, "halo vision": 72.65, "hepatic cytolysis": 5.59, "hepatic enzyme increased": 7.37, "hepatic failure": 2.86, "hepatic function abnormal": 11.96, "hepatitis": 2.52, "hepatitis cholestatic": 5.71, "hepatotoxicity": 33.46, "hyperbilirubinaemia": 2.39, "hypercalcaemia": 5.36, "hypertransaminasaemia": 6.66, "hypertrophic osteoarthropathy": 885.24, "hypokalaemia": 2.35, "immunosuppressant drug level increased": 17.98, "initial insomnia": 4.58, "liver disorder": 2.63, "liver function test abnormal": 5.89, "liver function test increased": 4.47, "liver injury": 19.9, "mental disorder": 8.46, "mental status changes": 2.31, "mucormycosis": 103.78, "multiple organ dysfunction syndrome": 5.26, "musculoskeletal pain": 2.99, "nephropathy toxic": 4.86, "nervous system disorder": 5.64, "neuropathy peripheral": 2.07, "neurotoxicity": 12.76, "off label use": 3.12, "pathogen resistance": 23.19, "periostitis": 2962.25, "photodermatosis": 165.16, "photophobia": 2.33, "photopsia": 6.32, "photosensitivity reaction": 49.18, "pneumonia fungal": 18.68, "polyneuropathy": 2.58, "product use in unapproved indication": 2.11, "pseudoporphyria": 390.14, "pulmonary mass": 3.79, "renal impairment": 2.95, "respiratory failure": 3.71, "rhabdomyolysis": 2.86, "scedosporium infection": 90.87, "septic shock": 3.38, "skin disorder": 3.76, "skin lesion": 3.95, "squamous cell carcinoma": 31.86, "squamous cell carcinoma of skin": 108.85, "systemic candida": 25.06, "therapeutic product effect incomplete": 2.91, "therapeutic response decreased": 3.08, "therapy non-responder": 2.32, "torsade de pointes": 7.2, "toxic epidermal necrolysis": 5.11, "toxic optic neuropathy": 186.65, "transaminases increased": 4.18, "treatment failure": 11.02, "vision blurred": 3.93, "visual impairment": 4.49, "vitreous floaters": 4.39, "xanthopsia": 83.93} |